Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
REGULATORY
Daiichi Sankyo’s Enhertu, Novartis’ Beovu, Novo’s Ozempic OK’ed for Listing on May 20
Japan’s all-important reimbursement policy panel on May 13 approved the listing of 18 drugs on May 20 including Daiichi Sankyo’s cancer drug Enhertu (trastuzumab deruxtecan) and Novartis’ wet age-related macular degeneration (AMD) treatment Beovu (brolucizumab). The Central Social Insurance Medical…
To read the full story
Related Article
- Novartis Launches AMD Drug Beovu in Japan
May 26, 2020
- Daiichi Sankyo’s Enhertu Hits Japan Market for Breast Cancer
May 26, 2020
- As Beovu Debut Nears, Novartis Set to Push Longer Dosing Interval, Pivotal Data in Battle against Eylea
May 22, 2020
- Nippon Shinyaku’s DMD Drug Now Available in Japan; AZ’s Lokelma, Ono’s Velexbru Too
May 21, 2020
- Japan OKs Enhertu, 3 Sakigake Drugs, Beovu, Latuda, and More
March 26, 2020
- Japan OKs Novo’s Single-Dose Pen Devices for List-Pending Ozempic
March 16, 2020
REGULATORY
- MHLW Issues Guidance to Thwart Distribution of Drugs with Unacceptable Nitrosamine Levels
January 10, 2025
- MHLW Panel to Draw Up Future Plan for Self-Medication Tax Break by This Summer
January 10, 2025
- MHLW Official Reveals Rationales Behind Off-Year Decision, Says PMP Return Is Reasonable
January 8, 2025
- PMDA Reviewing Safety Risks for Joyclu, Lixiana, Keytruda
January 7, 2025
- MHLW’s FY2025 Budget Includes 7.7 Billion Yen to Drive Drug Commercialization
January 6, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…